David A. Siegel Sangamo Therapeutics, Inc Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 820,355 shares of SGMO stock, worth $713,708. This represents 0.0% of its overall portfolio holdings.
Number of Shares
820,355
Previous 1,428,255
42.56%
Holding current value
$713,708
Previous $956,000
69.14%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding SGMO
# of Institutions
133Shares Held
86.3MCall Options Held
35.9KPut Options Held
156K-
Wasatch Advisors Inc Salt Lake City, UT20.1MShares$17.5 Million0.04% of portfolio
-
Armistice Capital, LLC New York, NY14.1MShares$12.2 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$10.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$4.09 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.56MShares$3.97 Million0.01% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $136M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...